News | September 04, 2025
Syntegon reports H1 2025 EBITDA higher by 41% to €127 million
Free cash flow also reached €63 million, representing an 11 percent increase compared to the high benchmark set in 2024
Free cash flow also reached €63 million, representing an 11 percent increase compared to the high benchmark set in 2024
He will be leading the design and execution of transformative strategies that harness the power of AI and automation, drive process optimization, and ignite digital innovation
He has successfully led the development of 15 approved drugs worldwide across various therapeutic areas over his more than 20-year career
First Indian company to follow global recommendations in accordance with the World Health Organisation (WHO)
Glenmark’s Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) Single-Dose Vials is bioequivalent and therapeutically equivalent to the reference listed drug, Halaven Injection, 1 mg/2 mL (0.5 mg/mL),of Eisai
Facility designed to advance the next generation of imaging systems
Enters the high growth vitamins, minerals and supplements segment for adults, paediatrics, and animal health
This PSD-3, the first pharmaceutical spray dryer built by GEA for OEB-5 products, sets new standards for high-containment pharmaceutical spray drying
Replicate will receive research funding and could potentially receive up to approximately US$550 million
Subscribe To Our Newsletter & Stay Updated
